Study of drug combo for returning brain lymphoma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of drugs (Orelabrutinib and Selinexor) with either Methotrexate, Thiotepa, or Temozolomide for people whose brain lymphoma has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with B-cell lymphoma that started in or spread to the brain.
- Your lymphoma has not responded to at least one prior treatment or has come back after treatment.
- You are between 14 and 80 years old.
- Your blood counts and liver, kidney, and clotting function are within certain limits.
- You are not pregnant or breastfeeding, and agree to use effective birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (teniposide, a PD-1 checkpoint inhibitor, and selinexor) for people with relapsed or refractory primary central nervous system lymphoma. It aims to see if this three-drug approach can shrink tumors or slow the disease when previous treatments haven't worked.
This trial tests a combination of three drugs (selinexor, high-dose methotrexate, and rituximab) plus radiation for people with newly diagnosed central nervous system (CNS) lymphoma who cannot have a stem cell transplant. The goal is to see if this treatment can help control the cancer.
This trial tests a new drug, zanubrutinib, combined with standard chemotherapy for people recently diagnosed with primary central nervous system lymphoma (a type of brain cancer). It aims to see if this combination is safe and effective.
This Phase 2 trial studies a combination of anti-cancer medicines to treat lymphoma that is only in the brain/spinal fluid (central nervous system, or CNS), especially when it has come back or not responded. If you qualify, you may benefit from improved tumor control and possibly better symptom control.
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
This trial tests a new combination of drugs (selinexor, temozolomide, and an immunotherapy) for people whose primary central nervous system lymphoma has come back or stopped responding to previous treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hear when a new Lymphoma Cns trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.